Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT "RIVAROXABAN TABLET" OBTAINS DRUG REGISTRATION CERTIFICATE

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

"RIVAROXABAN TABLET" OBTAINS DRUG REGISTRATION CERTIFICATE

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company", together with its subsidiaries, the "Group") announces that "Rivaroxaban Tablet" (brand name: Qingruixin（晴瑞欣）), a new oral anticoagulant developed by the Group, has obtained drug registration certificate granted by the National Medical Products Administration of the People's Republic of China and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs.

Rivaroxban is an oral drug that is highly selective and directly inhibits coagulation factor Xa, which interrupts the intrinsic and extrinsic pathways of the blood coagulation cascade by inhibiting factor Xa, thus inhibiting both thrombin formation and development of thrombi. Rivaroxban is suitable for preventing and reducing venous thrombosis events for patients who undergo elective hip or knee replacement surgeries, patients with deep vein thrombosis or pulmonary embolism, and patients with non-valvular atrial fibrillation, and has been included in Category B of the National Drug Catalogue for Medical Insurance. Compared with traditional anticoagulants, Rivaroxban has the advantages of rapid onset, predictable efficacy, and needless for routine coagulation monitoring and routine dosage adjustment.

The successive approval for launch of multiple anticoagulants of the Group symbolizes the continuous upgrade of the Group's comprehensive strength in the field of cardio-cerebrovascular therapy.

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 3 August 2020

1

As at the date of this announcement, the Board of the Company comprises eight Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.

2